FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to producing antibodies against the IgV domain of human TIM-3, and can be used in medicine for inhibiting human TIM-3, inhibiting TIM-3-mediated suppression of T cells in an individual, and treating TIM-3-positive malignant disease, as well as for detecting a human TIM-3-positive cell.
EFFECT: production of antibodies specifically binding to the IgV domain of human TIM-3 or IgV mucin-stem of human TIM-3 and containing a heavy chain with GYSFTGYTIN(CDR1), LFNPYNGGTT (CDR2), and ARRYYGYDAMDY (CDR3); as well as a light chain with KSSQSVLYSSNQKNHLA (CDR1); WASTRES (CDR2) and HQYLSSYT (CDR3).
22 cl, 6 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
